NCT00146783

Brief Summary

In areas of stable transmission, pregnant women, especially during the first and second pregnancies, have an increased susceptibility to Plasmodium falciparum malaria, malaria-related anaemia and an increased risk of having low birthweight babies. Intermittent Preventive Treatment in pregnancy(IPTp) with sulphadoxine-pyrimethamine has been shown to be effective in reducing the effects of malaria in pregnancy. This has mainly been in areas of perennial transmission and there is a need to study this effect in intense seasonal transmission settings. The emergence and spread of resistance to SP is likely to undermine its useful lifespan and it is important that other antimalarials that are safe and effective are identified for use in IPTp. The options are however limited. Amodiaquine has been shown to be effective in treatment of clinical cases of malaria, even in areas where chloroquine resistance is prevalent, and its combination with SP has been associated with favourable results. Both are affordable. However, there is limited data on their use in pregnancy. This study aims to assess the efficacy of SP in an area of intense seasonal transmission, and evaluate the safety and efficacy of amodiaquine and a combination of sulphadoxine-pyrimethamine and amodiaquine as possible alternatives to SP for use as IPTp.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
3,642

participants targeted

Target at P75+ for phase_2

Timeline
Completed

Started Jun 2004

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2004

Completed
1.3 years until next milestone

First Submitted

Initial submission to the registry

September 5, 2005

Completed
2 days until next milestone

First Posted

Study publicly available on registry

September 7, 2005

Completed
1.4 years until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2007

Completed
Last Updated

January 12, 2017

Status Verified

January 1, 2017

First QC Date

September 5, 2005

Last Update Submit

January 11, 2017

Conditions

Keywords

intermittent preventive treatmentmalariapregnancyefficacysafety

Outcome Measures

Primary Outcomes (1)

  • HB at delivery

    with inseven 7days of delivery

Secondary Outcomes (4)

  • placental malaria

    on the day of delivery

  • maternal peripheral parasitaemia at delivery

    within seven days of dellivery

  • tolerance and adverse events after taking study drugs

  • molecular markers of drug resistance to SP and Amodiaquine

Interventions

Eligibility Criteria

Age15 Years - 45 Years
Sexfemale
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Pregnant women with gestation between 18-32weeks,
  • willing to give written consent to take part in the study
  • Resident in the study area and available for follow-up.

You may not qualify if:

  • Presentation with clinical symptoms of malaria (this would not affect subsequent enrollment at a later date),
  • Known allergies or reactions to study drugs,
  • Medical conditions needing hospital admission.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Navrongo District Hosptial

Navrongo, Upper East Region, Ghana

Location

Related Publications (1)

  • Clerk CA, Bruce J, Affipunguh PK, Mensah N, Hodgson A, Greenwood B, Chandramohan D. A randomized, controlled trial of intermittent preventive treatment with sulfadoxine-pyrimethamine, amodiaquine, or the combination in pregnant women in Ghana. J Infect Dis. 2008 Oct 15;198(8):1202-11. doi: 10.1086/591944.

MeSH Terms

Conditions

Malaria

Interventions

fanasil, pyrimethamine drug combinationAmodiaquine

Condition Hierarchy (Ancestors)

Protozoan InfectionsParasitic DiseasesInfectionsMosquito-Borne DiseasesVector Borne Diseases

Intervention Hierarchy (Ancestors)

AminoquinolinesQuinolinesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic Compounds

Study Officials

  • Christine Clerk, MBChB, MSc

    London School of Hygiene and Tropical Medicine

    PRINCIPAL INVESTIGATOR
  • Daniel Chandramohan, MBBS, PhD

    London School of Hygiene and Tropical Medicine

    PRINCIPAL INVESTIGATOR
  • Brian Greenwood, FRCP, FRS

    London School of Hygiene and Tropical Medicine

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
DOUBLE
Purpose
PREVENTION
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

September 5, 2005

First Posted

September 7, 2005

Study Start

June 1, 2004

Study Completion

February 1, 2007

Last Updated

January 12, 2017

Record last verified: 2017-01

Locations